Application of dihydroartemisinin in medicines for treating sepsis-induced acute kidney injury

The invention provides application of dihydroartemisinin in medicines for treating sepsis-induced acute kidney injury. Tests prove that the dihydroartemisinin is capable of obviously inhibiting extremely high permeability of human renal glomerular endothelial cells (HRGECs) caused by a tumor necrosis factor TNF-alpha. The tests prove that the tumor necrosis factor TNF-alpha is capable of reducingexpressions of a tight junction protein Occludin in glomerulus, while the dihydroartemisinin has an effect of up-regulating expressions of the protein Occludin. Therefore, the results show that the dihydroartemisinin has the effect of reducing endothelial permeability of the glomerulus by up-regulating the expressions of the protein Occludin, so that the dihydroartemisinin is proved to have the ability of treating the sepsis-induced acute kidney injury. 本发明提供了双氢青蒿素在治疗脓毒症诱导的急性肾损伤药物中的应用。经试验证明，双氢青蒿素能够明显抑制肿瘤坏死因子TNFα引起的肾小球内皮细胞(HRGECs)通透性过高，试验证明，肿瘤坏死因子TNFα能够降低紧密连接蛋白Occludin在肾小球内皮细胞中的表达，而双氢青蒿素则具有上调Occludin蛋白表达的作用。因此，我们的结果表明双